BACKGROUND:Tuberculosis (TB) coinfection with human immunodeficiency virus (HIV) is a substantial problem in South Africa. There has been a presumption that drug-resistant strains of TB are common in South Africa, but few studies have documented this impression. METHODS: In Phidisa, a joint observational and randomized HIV treatment study for South African National Defence Force members and dependents, an initiative was launched to test subjects (by use of microbiologic TB test) who appeared to be at high risk. We report results for HIV-infected subjects. RESULTS:TB was identified by culture in 116 (19.9%) of 584 patients selected for sputum examination on the basis of suggestive symptoms. Smear was an insensitive technique for confirming the diagnosis: only 33% of culture-positive patients were identified by smear, with a 0.2% false-positive rate. Of the 107 culture-positive individuals with susceptibility testing, 22 (20.6%) were identified to be multidrug resistant (MDR), and 4 (3.7%) were identified to be extensively drug resistant. Culture-positive cases with a history of TB treatment had more than twice the rate of MDR than those without (27.1% vs 11.9%; P = .05). CONCLUSIONS:TB is common in this cohort of HIV-infected patients. Smear was not a sensitive technique for identifying culture-positive cases in this health system. Drug susceptibility testing is essential to proper patient management because MDR was present in 20.6% of culture-positive patients. Better management strategies are needed to reduce the development of MDR TB, because so many of these patients had received prior antituberculous therapy that was presumably not curative.
RCT Entities:
BACKGROUND:Tuberculosis (TB) coinfection with human immunodeficiency virus (HIV) is a substantial problem in South Africa. There has been a presumption that drug-resistant strains of TB are common in South Africa, but few studies have documented this impression. METHODS: In Phidisa, a joint observational and randomized HIV treatment study for South African National Defence Force members and dependents, an initiative was launched to test subjects (by use of microbiologic TB test) who appeared to be at high risk. We report results for HIV-infected subjects. RESULTS: TB was identified by culture in 116 (19.9%) of 584 patients selected for sputum examination on the basis of suggestive symptoms. Smear was an insensitive technique for confirming the diagnosis: only 33% of culture-positive patients were identified by smear, with a 0.2% false-positive rate. Of the 107 culture-positive individuals with susceptibility testing, 22 (20.6%) were identified to be multidrug resistant (MDR), and 4 (3.7%) were identified to be extensively drug resistant. Culture-positive cases with a history of TB treatment had more than twice the rate of MDR than those without (27.1% vs 11.9%; P = .05). CONCLUSIONS: TB is common in this cohort of HIV-infectedpatients. Smear was not a sensitive technique for identifying culture-positive cases in this health system. Drug susceptibility testing is essential to proper patient management because MDR was present in 20.6% of culture-positive patients. Better management strategies are needed to reduce the development of MDR TB, because so many of these patients had received prior antituberculous therapy that was presumably not curative.
Authors: Yvonne R Shea; J Lucian Davis; Laurence Huang; Joseph A Kovacs; Henry Masur; Francis Mulindwa; Sally Opus; Yuenwah Chow; Patrick R Murray Journal: J Clin Microbiol Date: 2009-03-18 Impact factor: 5.948
Authors: J Bruchfeld; G Aderaye; I B Palme; B Bjorvatn; G Källenius; L Lindquist Journal: Trans R Soc Trop Med Hyg Date: 2000 Nov-Dec Impact factor: 2.184
Authors: Graeme Meintjes; Molebogeng X Rangaka; Gary Maartens; Kevin Rebe; Chelsea Morroni; Dominique J Pepper; Katalin A Wilkinson; Robert J Wilkinson Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Amina Abdelaal; Hassan Abd El-Ghaffar; Mohammad Hosam Eldeen Zaghloul; Noha El Mashad; Ehab Badran; Amal Fathy Journal: Ann Clin Microbiol Antimicrob Date: 2009-01-30 Impact factor: 3.944
Authors: Paras Jain; Travis E Hartman; Nell Eisenberg; Max R O'Donnell; Jordan Kriakov; Karnishree Govender; Mantha Makume; David S Thaler; Graham F Hatfull; A Willem Sturm; Michelle H Larsen; Preshnie Moodley; William R Jacobs Journal: J Clin Microbiol Date: 2012-01-25 Impact factor: 5.948
Authors: P K Drain; L Mayeza; P Bartman; R Hurtado; P Moodley; S Varghese; G Maartens; G G Alvarez; D Wilson Journal: Int J Tuberc Lung Dis Date: 2014-01 Impact factor: 2.373
Authors: Max R O'Donnell; Alexander Pym; Paras Jain; Vanisha Munsamy; Allison Wolf; Farina Karim; William R Jacobs; Michelle H Larsen Journal: J Clin Microbiol Date: 2015-04-29 Impact factor: 5.948
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Janet Giddy; Douglas Ross; Jeffrey N Katz; Ingrid V Bassett Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Paras Jain; David S Thaler; Mamoudou Maiga; Graham S Timmins; William R Bishai; Graham F Hatfull; Michelle H Larsen; William R Jacobs Journal: J Infect Dis Date: 2011-11-15 Impact factor: 5.226
Authors: Jason R Andrews; N Sarita Shah; Darren Weissman; Anthony P Moll; Gerald Friedland; Neel R Gandhi Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Janet Giddy; Douglas Ross; Jeffrey N Katz; Rochelle P Walensky; Kenneth A Freedberg; Ingrid V Bassett Journal: BMC Infect Dis Date: 2014-02-26 Impact factor: 3.090